A

simmering clash between brand-name and generic drug makers may be reviewed by the US Supreme Court on Friday, and the outcome could determine some key procedural steps for pharmaceutical patent litigation. And this, in turn, might influence just how fast copycat drugs can get to market.

At issue is the legal concept of jurisdiction which, essentially, refers to the location of the court where a lawsuit is heard. And venues can be important, especially since some courts may be better equipped than others to sort out complex challenges to prescription drug patents.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.

X